



FORM PTO-1449
INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.

20490.003

APPLICATION NO.

10/569,076

APPLICANTS

Wolfgang E. BERDEL *et al.*

FILING DATE

February 21, 2006

GROUP

To Be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA1						
	AB1						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
/MA/	AC1	WO 03/035688 A	05/2003	WIPO			Yes No
	AD1						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

/MA/	AE1	Arap <i>et al.</i> , "Cancer Treatment by Targeted Drug Delivery to Tumor Vasculature in a Mouse Model", <i>Science</i> 279:377-380 (1998)					
	AF1	Banner <i>et al.</i> , "The Crystal Structure of the Complex of Blood Coagulation Factor VIIa with Soluble Tissue Factor", <i>Nature</i> 380:41-46 (1996)					
	AG1	Bhagwa <i>et al.</i> , "CD13/APN is Activated by Angiogenic Signals and is Essential for Capillary Tube Formation", <i>Blood</i> 97(3):652-659 (2001)					
	AH1	Brooks <i>et al.</i> , "Requirement of Vascular Integrin $\alpha_v\beta_3$ for Angiogenesis", <i>Science</i> 264:569-571 (1994)					
	AI1	Brooks <i>et al.</i> , "Integrin $\alpha_v\beta_3$ Antagonists Promote Tumor Regression by Inducing Apoptosis of Angiogenic Blood Vessels", <i>Cell</i> 79:1157-1164 (1994)					
	AJ1	Brooks <i>et al.</i> , "Localization of Matrix Metalloproteinase MMP-2 to the Surface of Invasive Cells by Interaction with Integrin $\alpha_v\beta_3$ ", <i>Cell</i> 85:683-693 (1996)					
	AK1	Brooks <i>et al.</i> , "Disruption of Angiogenesis by PEX, a Noncatalytic Metalloproteinase Fragment with Integrin Binding Activity", <i>Cell</i> , 92:391-400 (1998)					
	AL1	Burg <i>et al.</i> , "NG2 Proteoglycan-Binding Peptides Target Tumor Neovasculature", <i>Cancer Research</i> 59:2869-2874 (1999)					
	AM1	Burrows <i>et al.</i> , "Up-Regulation of Endoglin on Vascular Endothelial Cells in Human Solid Tumors: Implications for Diagnosis and Therapy", <i>Clinical Cancer Research</i> 1:1623-1634 (1995)					

EXAMINER

/Marianne Allen/

DATE CONSIDERED

05/12/2008

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO.	APPLICATION NO.
		20490.003	10/569,076
		APPLICANTS	
		Wolfgang E. BERDEL <i>et al.</i>	
		FILING DATE	GROUP
		February 21, 2006	To Be Assigned

/MA/	ANI	Carnemolla <i>et al.</i> , "A Tumor-associated Fibronectin Isoform Generated by Alternative Splicing of Messenger RNA Precursors", <i>The Journal of Cell Biology</i> 108:1139-1148 (1989)
	AOI	Curnis <i>et al.</i> , "Enhancement of Tumor Necrosis Factor α Antitumor Immunotherapeutic Properties by Targeted Delivery to Aminopeptidase N (CD13)", <i>Nature Biotechnology</i> 18:1185-1190 (2000)
	API	Curnis <i>et al.</i> , "Differential Binding of Drugs Containing the NGR Motif to CD13 Isoforms in Tumor Vessels, Epithelia, and Myeloid Cells", <i>Cancer Research</i> 62:867-874 (2002)
	AQI	Dvorak <i>et al.</i> , "Distribution of Vascular Permeability Factor (Vascular Endothelial Growth Factor) in Tumors: Concentration in Tumor Blood Vessels", <i>J. Exp Med.</i> 174:1275-1278 (1991)
	ARI	Dvorak <i>et al.</i> , "Vascular Permeability Factor/Vascular Endothelial Growth Factor, Microvascular Hyperpermeability, and Angiogenesis", <i>American Journal of Pathology</i> , 146(5):1029-1039 (1995)
	ASI	Ellerby <i>et al.</i> , "Anti-Cancer Activity of Targeted Pro-Apoptotic Peptides", <i>Nature Medicine</i> , 5(9):1032-1038 (1999)
	ATI	Folkman <i>et al.</i> , "Induction of Angiogenesis During the Transition from Hyperplasia to Neoplasia", <i>Nature</i> 339:58-61 (1989)
	AUI	Gottstein <i>et al.</i> , "Generation and Characterization of Recombinant Vascular Targeting Agents from Hybridoma Cell Lines", <i>BioTechniques</i> 30(1):190-199 (2001)
	AVI	Healy <i>et al.</i> , "Peptide Ligands for Integrin $\alpha_v\beta_3$ Selected from Random Phage Display Libraries", <i>Biochemistry</i> 34:3948-3955 (1995)
	AWI	Hu <i>et al.</i> , "Comparison of Three Different Targeted Tissue Factor Fusion Proteins for Inducing Tumor Vessel Thrombosis", <i>Cancer Research</i> 63:5046-5053 (2003)
	AXI	Huang <i>et al.</i> , "Tumor Infarction in Mice by Antibody-directed Targeting of Tissue Factor to Tumor Vasculature", <i>Science</i> 275:547-550 (1997)
	AYI	International Search Report of PCT/EP2004/009364 mailed February 23, 2005.
	AZI	Koivunen <i>et al.</i> , "Selection of Peptides Binding to the $\alpha_v\beta_1$ Integrin from Phage Display Library", <i>The Journal of Biological Chemistry</i> , 268(27):20205-20210 (1993)

considered, do not
print

EXAMINER	DATE CONSIDERED
/Marianne Allen/	05/12/2008
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>		ATTY. DOCKET NO.	APPLICATION NO.
		20490.003	10/569,076
		APPLICANTS	
		Wolfgang E. BERDEL <i>et al.</i>	
		FILING DATE	GROUP
		February 21, 2006	To Be Assigned

	AA2	Koivunen <i>et al.</i> , "Tumor Targeting with a Selective Gelatinase Inhibitor", <i>Nature Biotechnology</i> 17:768-774 (1999)
	AB2	Liu <i>et al.</i> , "Prostate-specific Membrane Antigen Directed Selective Thrombotic Infarction of Tumors", <i>Cancer Research</i> 62:5470-5475 (2002)
	AC2	Maisonpierre <i>et al.</i> , "Angiopoietin-2, a Natural Antagonist for Tie2 That Disrupts In Vivo Angiogenesis", <i>Science</i> 277:55-60 (1997)
	AD2	Morrissey <i>et al.</i> , "Quantitation of Activated Factor VII Levels in Plasma Using a Tissue Factor Mutant Selectively Deficient in Promoting Factor VII Activation", <i>Blood</i> 81(3):734-744 (1993)
	AE2	Nilsson <i>et al.</i> , "Targeted Delivery of Tissue Factor to the ED-B Domain of Fibronectin, a Marker of Angiogenesis, Mediates the Infarction of Solid Tumors in Mice", <i>Cancer Research</i> 61:711-716 (2001)
	AF2	Olsen <i>et al.</i> , "Targeting the Tumor Vasculature: Inhibition of Tumor Growth by a Vascular Endothelial Growth Factor-Toxin Conjugate", <i>Int. J. Cancer</i> 73:865-870 (1997)
	AG2	Pasqualini <i>et al.</i> , "Aminopeptidase N Is a Receptor for Tumor-homing Peptides and a Target for Inhibiting Angiogenesis", <i>Cancer Research</i> 60:722-727 (2000)
	AH2	Peters <i>et al.</i> , "Expression of Tie2/Tek in Breast Tumour Vasculature Provides a New Marker for Evaluation of Tumour Angiogenesis", <i>British Journal of Cancer</i> 77(1):51-56 (1998)
	AI2	Ran <i>et al.</i> , "Infarction of Solid Hodgkin's Tumors in Mice by Antibody-directed Targeting of Tissue Factor to Tumor Vasculature", <i>Cancer Research</i> 58:4646-4653 (1998)
	AJ2	Rettig <i>et al.</i> , "Identification of Endosialin, a Cell Surface Glycoprotein of Vascular Endothelial Cells in Human Cancer", <i>Proc. Natl. Acad. Sci. USA</i> 89:10832-10836 (1992)
	AK2	Rippmann <i>et al.</i> , "Fusion of the Tissue Factor Extracellular Domain to a Tumour Stromaspecific Single-Chain Fragment Variable Antibody Results in an Antigen-Specific Coagulation-Promoting Molecule", <i>Biochemical Journal</i> 349(3):805-812 (2000)
AL2	Ruf <i>et al.</i> , "Phospholipid-independent and -dependent Interactions Required for Tissue Factor Receptor and Cofactor Function", <i>The Journal of Biological Chemistry</i> , 266(4):2158-2166 (1991)	
AM2	Ruoslahti, "Targeting Tumor Vasculature with Homing Peptides from Phage Display", <i>Seminars in Cancer Biology</i> 10:435-442 (2000)	

EXAMINER	/Marianne Allen/	DATE CONSIDERED	05/12/2008
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.			

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>		ATTY. DOCKET NO.	APPLICATION NO.
		20490.003	10/569,076
		APPLICANTS	
		Wolfgang E. BERDEL <i>et al.</i>	
		FILING DATE	GROUP
		February 21, 2006	To Be Assigned
/MA/	AN2	Scholz <i>et al.</i> , "Correlation of Drug Response in Patients and in the Clonogenic Assay with Solid Human Tumour Xenografts", <i>Eur J. Cancer</i> 26(8):901-905 (1990)	
	AO2	Schnürch <i>et al.</i> , "Expression of tie-2, a Member of a Novel Family of Receptor Tyrosine Kinases, In the Endothelial Cell Lineage", <i>Development</i> 119:957-968 (1993)	
	AP2	Schrappe <i>et al.</i> , "Correlation of Chondroitin Sulfate Proteoglycan Expression on Proliferating Brain Capillary Endothelial Cells with the Malignant Phenotype of Astroglial Cells", <i>Cancer Research</i> 51:4986-4993 (1991)	
	AQ2	Senger <i>et al.</i> , "Angiogenesis Promoted by Vascular Endothelial Growth Factor: Regulation Through $\alpha_1\beta_1$ and $\alpha_2\beta_1$ Integrins", <i>Proc. Natl. Acad. Sci. USA</i> 94:13612-13617 (1997)	
	AR2	Suri <i>et al.</i> , "Requisite Role of Angiopoietin-1, a Ligand for the TIE2 Receptor, During Embryonic Angiogenesis", <i>Cell</i> 87:1171-1180 (1996)	
	AS2	Terman <i>et al.</i> , "Biological Properties of VEGF/VPF Receptors", <i>Cancer and Metastasis Reviews</i> 15:159-163 (1996)	
	AT2	Topp <i>et al.</i> , "Recombinant Human Interleukin-4 Inhibits Growth of Soe Human Lung Tumor Cell Lines In Vitro and In Vivo", <i>Blood</i> 82(9):2837-2844 (1993)	
	AU2	Topp <i>et al.</i> , "Recombinant Human Interleukin 4 Has Antiproliferative Activity on Human Tumor Cell Lines Derived from Epithelial and Nonepithelial Histologies", <i>Cancer Research</i> 55:2173-2176 (1995)	
↓	AV2	Yun <i>et al.</i> , "Involvement of Integrin $\alpha_v\beta_3$ in Cell Adhesion, Motility, and Liver Metastasis of Murine RAW117 Large Cell Lymphoma", <i>Cancer Research</i> 56:3103-3111 (1996)	
	AW2		

EXAMINER	/Marianne Allen/	DATE CONSIDERED	05/12/2008
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.			